Cart
sales@molnova.com
GLP-26
CAS No. 2133017-36-2
GLP-26( GLP26 )
Catalog No. M13398 CAS No. 2133017-36-2
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 124 | In Stock |
|
| 5MG | 133 | In Stock |
|
| 10MG | 181 | In Stock |
|
| 25MG | 281 | In Stock |
|
| 50MG | 401 | In Stock |
|
| 100MG | 551 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGLP-26
-
NoteResearch use only, not for human use.
-
Brief DescriptionGLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.
-
DescriptionGLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM; GLP26 is a potent inhibitor of cccDNA formation and HBeAg production against the mutant core T109I, demonstrates synergistic activity with ETV in the HepAD38 system, reducing HBV DNA replication.
-
In VitroCell Viability Assay Cell Line:HepNTCP-DL cells Concentration:0.7-1.7 μM Incubation Time:3 days Result:Reduced secreted HBeAg in HepNTCP-DL cells.
-
In Vivo——
-
SynonymsGLP26
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2133017-36-2
-
Formula Weight373.36
-
Molecular FormulaC19H17F2N3O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (334.81 mM)
-
SMILESCC1=C(N(C(=C1C(=O)C(=O)NCC#C)C)C)C(=O)NC2=CC(=C(C=C2)F)F
-
Chemical NameN-(3,4-difluorophenyl)-1,3,5-trimethyl-4-(2-oxo-2-(prop-2-yn-1-ylamino)acetyl)-1H-pyrrole-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
RG7834
RG7834 is a highly selective and orally bioavailable inhibitor of HBV(HBsAg and HBeAg and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells).
-
Metacavir
Metacavir (PNA) is a novel nucleoside reverse transcriptase inhibitor, a deoxyguanosine analog, with anti-hepatitis B virus (HBV) activity and mitochondrial toxicity, which can be used to study HBV infection.
-
GLS4
GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM).
